Table 2.
Laboratory parameters in T2D patients with albuminuric and non-albuminuric CKD
| Parameter | CKD− | NA-CKD | A-CKD− | A-CKD+ | |
|---|---|---|---|---|---|
| N | 33 | 33 | 32 | 32 | |
| Renal tests | |||||
| Serum creatinine, μmol/L | 76 (68; 87) | 111 (102; 124) *** | 87 (79; 97) §§§ ### | 117 (98; 144) *** | |
| eGFR, mL/min/1.73 m2 | 84 (73; 94) | 51 (45; 55) *** | 71 (65; 77) §§§ ### | 51 (43; 55) *** | |
| UACR, mg/mmol | 0.6 (0.3; 0.9) | 0.6 (0.3; 0.9) | 13.5 (6.4; 38.4) *** ### | 14.1 (7.2; 82.5) *** ### | |
| Urinary nephrin excretion, ng/mmol | 12.1 (4.7; 21.1) | 7.8 (4.1; 16.3) | 22.6 (16.6; 36.2) *** ### | 22.2 (17.1; 32.9) *** ### | |
| Urinary podocin excretion, ng/mmol | 133 (86; 222) | 105 (65.4; 193.9) | 250 (144; 421) *** ### | 268 (134; 411) *** ### | |
| Urinary excretion of WFDC2, ng/mmol | M | 442 (310; 941) +++ | 723 (406; 811) +++ | N/D | 628 (410; 1277) +++ |
| F | 5.6 (0; 81) | 129 (0; 330) ** | N/D | 231 (110; 619) ** | |
| Other biochemical parameters | |||||
| HbA1C | % | 8.48 (7.5; 9.8) | 9.06 (7.9; 10.26) | 9.36 (8.25; 11.58) | 8.81 (7.64; 10.1) |
| mmol/mol | 69 (58; 84) | 76 (63; 89) | 79 (67; 103) | 73 (60; 87) | |
| Total cholesterol, mmol/L | 4.92 (4.32; 5.51) | 5.14 (4.11; 6.07) | 4.89 (4.06; 5.89) | 5.5 (4.19; 6.25) | |
| LDL-cholesterol, mmol/L | 3.02 (2.7; 3.59) | 3.21 (2.51; 3.92) | 3.19 (2.6; 3.95) | 3.26 (2.54; 4.18) | |
| HDL-cholesterol, mmol/L | 1.13 (1; 1.31) | 1.22 (1.09; 1.41) | 1.07 (0.93; 1.25) # | 1.12 (1; 1.41) | |
| Triglycerides, mmol/L | 1.76 (1.15; 2.47) | 1.9 (1.5; 2.6) | 2.2 (1.64; 3.3) | 1.93 (1.54; 3.08) | |
| Uric acid, μmol/L | 298 (243; 352) | 341 (315; 392) | 322 (281; 383) | 366 (272; 418) | |
| Serum hs-CRP, mg/L | 4.1 (2.3; 8.2) | 6.2 (2.3; 8.4) | 4.4 (1.4; 7.3) | 6.7 (2.2; 13.1) | |
| Hematology and coagulation tests | |||||
| Hemoglobin, g/L | 139 (131; 148) | 141 (128; 151) | 141 (127; 152) | 141 (126; 153) | |
| RBC, × 1012/L | 4.79 (4.5; 4.9) | 4.72 (4.44; 5.06) | 4.85 (4.6; 5.13) | 4.7 (4.26; 4.87) | |
| WBC, × 109/L | 6.18 (5.93; 7.65) | 7.44 (5.61; 8.34) | 7.52 (6.03; 8.85) | 7.31 (5.53; 8.15) | |
| Platelets, × 109/L | 244 (218; 269) | 253 (207; 282) | 247 (212; 278) | 206 (181; 275) | |
| ESR, mm/h | 15 (9; 22) | 19 (12; 26.5) | 22.5 (15.5; 29) | 23.5 (18; 30) ** | |
| Fibrinogen, g/L | 4.15 (3.3; 5.3) | 3.9 (3.2; 4.45) | 4.4 (3.7; 5.5) | 4.6 (4; 5.3) | |
| SFMCs, mg/dL | 4 (3.5; 13.5) | 14 (3.5; 21) | 10.5 (6; 21.5) | 12 (8; 19) | |
| D-dimer, ng/mL | 255 (215; 309) | 251 (231; 385) | 268 (231; 297) | 277 (238; 327) | |
Continues data are presented as medians (lower quartile; upper quartile), ** p < 0.01, *** p < 0.001 vs. CKD−, # p < 0.05, ### p < 0.001 vs. NA-CKD, §§§ p < 0.001 vs. A-CKD+, +++p < 0.001 vs. female patients with T2D; Mann–Whitney and Kruskal–Wallis test, Holm’s step-down procedure. CKD−: The group of individuals with estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2 and urinary albumin-to-creatinine ratio (UACR) <3.0 mg/mmol; NA-CKD: Non-albuminuric chronic kidney disease, the group of individuals with eGFR <60 mL/min/1.73 m2 and UACR <3.0 mg/mmol; A-CKD−: Group of patients with eGFR ≥60 mL/min/1.73 m2 and UACR ≥3.0 mg/mmol; A-CKD+: Group of individuals with eGFR <60 mL/min/1.73 m2 and UACR ≥3.0 mg/mmol; hs-CRP, high-sensitively C-reactive protein; WFDC2, whey acidic protein four-disulfide core domain protein 2.